KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED)

Rhea-AI Summary

KALA BIO (NASDAQ:KALA) has announced a virtual Key Opinion Leader (KOL) event scheduled for July 16, 2025, at 4:00 p.m. ET. The event will focus on KPI-012, their investigational treatment for persistent corneal epithelial defect (PCED).

The webcast will feature presentations from distinguished ophthalmology experts including Dr. Francis Mah from Scripps Clinic, Dr. Anthony Aldave from Jules Stein Eye Institute, Dr. Stephen Pflugfelder from Baylor College of Medicine, and Dr. Melissa Toyos from Toyos Clinic. The discussion will cover PCED disease overview, unmet needs, and insights into the CHASE clinical trial. Todd Bazemore, interim CEO, will discuss KPI-012's commercial potential and upcoming milestones.

ARLINGTON, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss the potential of KPI-012 for the treatment of persistent corneal epithelial defect (PCED). The event will take place on Wednesday, July 16, 2025, at 4:00 p.m. ET.

The webcast event will feature presentations from:

• Francis Mah, M.D., Director of Cornea and External Disease & Co-Director, Refractive Surgery at Scripps Clinic Medical Group
• Anthony Aldave, M.D., Professor of Ophthalmology, Co-Chief of the Cornea and Uveitis Division at Jules Stein Eye Institute
• Stephen Pflugfelder, M.D., Professor and James and Margret Elkins Chair in Ophthalmology at Baylor College of Medicine
• Melissa Toyos, M.D., Partner, Research Director, Comprehensive Ophthalmology at Toyos Clinic

The speakers will provide a disease overview of PCED, including the unmet need and patient journey, as well as insights into mesenchymal stem cell secretome (MSC-S), KPI-012 and the CHASE clinical trial experience. In addition, Todd Bazemore, interim Chief Executive Officer and President of KALA BIO, will review the commercial opportunity of KPI-012 and upcoming milestones.

There will be an opportunity for Q&A following the presentation. Participants can register for the live webcast here. In addition, a live webcast of the presentation will be available under “Presentations” in the Investor section of the Company’s website at www.kalarx.com. An archived replay will be available on the Company's website following the presentation.

About KALA BIO, Inc.

KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.

Investor Contact:

Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200

FAQ

When is KALA BIO's KOL event for KPI-012 and how can investors attend?

The virtual KOL event is scheduled for July 16, 2025, at 4:00 p.m. ET. Investors can register for the live webcast through KALA's provided link or access it under the 'Presentations' section on www.kalarx.com.

Who are the key speakers at KALA BIO's KPI-012 KOL event?

The event features four distinguished speakers: Dr. Francis Mah (Scripps Clinic), Dr. Anthony Aldave (Jules Stein Eye Institute), Dr. Stephen Pflugfelder (Baylor College of Medicine), and Dr. Melissa Toyos (Toyos Clinic).

What topics will be covered at KALA's KPI-012 KOL event?

The event will cover PCED disease overview, unmet patient needs, patient journey, insights into mesenchymal stem cell secretome (MSC-S), KPI-012, CHASE clinical trial experience, and commercial opportunities.

Where can investors access the replay of KALA's KPI-012 KOL presentation?

An archived replay of the presentation will be available in the 'Presentations' section of KALA BIO's website at www.kalarx.com following the event.